

REMARKS

Claims 1-44 are pending in this application. The Examiner has required restriction to one of five groups. In response to such restriction, Applicants wish to proceed as follows.

Applicants elect Group IV (claims 13 and 34-42), drawn to a sustained release formulation of lamotrigine comprising a core (lamotrigine), an outer coating covering said core, said outer coating including one or more orifices extending from the outside of the coating, for proceeding with prosecution on the merits.

Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to effect the timely filing of this paper, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,



Bonnie L. Deppenbrock
Attorney for Applicants
Registration No. 28,209

Date: 3 April 2007
Customer No. 23347
GlaxoSmithKline
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709
Telephone: (919) 483-1577
Facsimile: (919) 483-7988

ELECTRONICALLY FILED USING THE EFS-WEB ELECTRONIC FILING SYSTEM OF THE UNITED STATES
PATENT & TRADEMARK OFFICE ON 4/4/07